Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$4.44 -0.2%	$3.44	$2.01 ▼ $5.64	$295.79M	1.52	1.22 million shs	898,236 shs
NGNE Neurogene	$23.26 +2.9%	$18.99	$6.88 ▼ $74.49	$331.40M	1.51	250,944 shs	37,355 shs
OTLK Oncobiologics	$2.17 -6.3%	$1.81	$0.87 ▼ $8.70	$72.68M	0.25	671,105 shs	475,803 shs
PRQR ProQR Therapeutics	$2.33 -3.1%	$1.91	$1.07 ▼ $4.62	$244.61M	0.36	446,728 shs	173,606 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+0.68%	+6.97%	+20.27%	+56.14%	+75.20%
NGNE Neurogene	+0.27%	+2.91%	+22.69%	+96.69%	-49.03%
OTLK Oncobiologics	-4.15%	+14.36%	+36.69%	+59.31%	-74.19%
PRQR ProQR Therapeutics	+2.13%	+1.69%	+26.98%	+110.53%	+30.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.1719 of 5 stars	3.4	0.0	1.6	0.0	0.6
NGNE Neurogene	3.4527 of 5 stars	4.4	2.0	2.7	2.5	0.6
OTLK Oncobiologics	2.5558 of 5 stars	3.4	4.0	2.8	0.0	0.6
PRQR ProQR Therapeutics	2.6091 of 5 stars	3.6	5.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	163.34% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	98.49% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	343.42% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	244.09% Upside

Current Analyst Ratings Breakdown

Latest OTLK, PRQR, NGNE, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	434.70	N/A	N/A	$1.86 per share	2.39
NGNE Neurogene	$930K	356.64	N/A	N/A	$20.89 per share	1.11
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.96	N/A	N/A	$0.91 per share	2.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest OTLK, PRQR, NGNE, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q3 2025	OTLK Oncobiologics	-$0.42	N/A	N/A	N/A	$1.66 million	N/A
8/8/2025	Q2 2025	NGNE Neurogene	-$1.15	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
NGNE Neurogene	N/A	21.03	21.03
OTLK Oncobiologics	N/A	0.72	0.57
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
NGNE Neurogene	52.37%
OTLK Oncobiologics	11.20%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
NGNE Neurogene	11.64%
OTLK Oncobiologics	4.80%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

OTLK, PRQR, NGNE, and CRDF Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's Why

July 8, 2025 | marketbeat.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from Brokerages

June 30, 2025 | marketbeat.com

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

June 27, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK, PRQR, NGNE, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$4.44 0.00 (-0.11%)

As of 01:21 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Neurogene NASDAQ:NGNE

$23.26 +0.66 (+2.92%)

As of 01:20 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Oncobiologics NASDAQ:OTLK

$2.16 -0.15 (-6.28%)

As of 01:20 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

ProQR Therapeutics NASDAQ:PRQR

$2.33 -0.08 (-3.13%)

As of 01:20 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time